Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)

NCT06155500 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease

Interventions

BIOLOGICAL: OTQ923

Sponsor

Novartis Pharmaceuticals